glp 1 dementia study Can GLP-1 agonists and SGLT-2 inhibitors decrease risk?, Two recent JAMA Neurology studies examined the association., 🔗 Read more via our link in bio GLP-1 and neurodegeneration: lessons from

The CJC-1295 Ipamorelin research guide and the CJC-1295 Ipamorelin blend product provide detailed research context for this pairing

The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone ( P = 0.027), with a median within-patient difference of 10.4 (Hedge g = 0.62 (95% confidence interval: 1.43, 0.08))

10.1046/j.1523-1755.2002.00153.x 66 KimH

The switch may cause transient weight fluctuation (1 to 3 pounds) during washout or titration, but this does not erase prior progress